Physician profile
John B Buttross
NPI 1053370213
$5,940.78
in general payments reported to CMS, 2019-2025
43 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $711 · 2021: $1,538 · 2022: $756 · 2023: $506 · 2024: $452 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,224.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $537.36 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $505.23 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $467.09 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $375.99 | 2019-2022 | |
| Abbott Laboratories | $316.41 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $205.35 | 2019-2025 | |
| Astellas Pharma US INC | $166.31 | 2020-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $159.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.95 | 2021-2025 | Jardiance, Ofev |
| Eisai INC. | $137.22 | 2020-2021 | |
| Allergan, INC. | $131.96 | 2019-2020 | |
| Lilly USA, LLC | $127.00 | 2022-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $117.44 | 2021-2025 | Trintellix |
| Seqirus USA INC | $93.59 | 2021-2025 | Fluad, Flucelvax |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Buttross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.